Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory postmenopausal women.~* Age 55 years or older~* Subject has provided informed consent prior to any study specific procedures~* Received oral bisphosphonate therapy for osteoporosis at least 2 years prior to screening visit~* Screening BMD (g/cm²) values at the lumbar spine, total hip or femoral neck values of equal to or less than those listed in the protocol.~* At least 2 lumbar vertebrae and one hip must be evaluable by dual energy x-ray absorptiometry (DXA) at the screening visit~Exclusion Criteria:~* Received other osteoporosis treatment or bone active treatment~* Evidence of history of any of the following:~  * hyperthyroidism (stable on antithyroid therapy is allowed)~ * hypothyroidism (stable on thyroid replacement therapy is allowed)~ * hypo- or hyperparathyroidism~ * hypo- or hypercalcemia based on the central laboratory reference ranges~ * Recent tooth extraction (within 6 months of screening visit)~ * Paget disease of bone (subject report or chart review)~ * other bone diseases which affect bone metabolism (eg, osteopetrosis, osteogenesis imperfecta) (chart review)~* Abnormalities of the following per central laboratory reference ranges:~  * vitamin D deficiency (25\[OH\] vitamin D level \< 20 ng/mL), repletion will be allowed and subjects may be re-screened~ * hypercalcemia~ * elevated transaminases ≥ 2.0 x upper limits of normal (ULN)~* History of any solid organ or bone marrow transplant~* Malignancy (except nonmelanoma skin cancers, cervical or breast ductal carcinoma in situ) within the last 5 years~* Known intolerance to calcium or vitamin D supplements~* Self-reported alcohol or drug abuse within 12 months prior to screening~* Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s)~* History or evidence of any other clinically significant disorder, condition or disease that in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab 60 mg (Type: EXPERIMENTAL): Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
- Zoledronic Acid 5 mg (Type: ACTIVE_COMPARATOR): Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).